Nektar boosts R&D presence in San Francisco

Nektar Therapeutics ($NKTR) has announced a move to consolidate all of its U.S. research and development at its Mission Bay location in San Francisco. The company, a maker and developer of PEGylated drugs, plans to relocate 30 R&D workers from its research site in Huntsville, AL, to Mission Bay by July as part of the move. The company plans to keep manufacturing operations in Alabama, however. The San Francisco Business Times reports that the company, which will also keep its research outpost in India, plans to cut 5 jobs in Alabama. Article